First Successful CRISPR Gene Editing in Humans

You can't point to a single moment when CRISPR first succeeded in humans — it's a story that keeps rewriting itself. In 2013, scientists proved it could work in human cells. By 2016, Chinese doctors injected edited cells into a cancer patient. In 2023, the FDA approved the first CRISPR medicine. Then in 2025, a baby received a fully personalized base-editing therapy built in six months. Each breakthrough redefined what "successful" actually means — and there's much more to unpack.

Key Takeaways

• In 2016, Chinese researchers conducted the first CRISPR human trial, injecting edited immune cells into a lung cancer patient.
• A 55-year-old lung cancer patient experienced tumor shrinkage lasting 75 weeks following CRISPR-edited cell treatment.
• The 2013 lab experiment proving CRISPR worked in human cells transformed it from a theoretical to practical tool.
• In 2023, the FDA approved Casgevy, a CRISPR therapy for sickle cell disease and β-thalassemia patients aged 12+.
• In 2025, a personalized base editing therapy was developed, tested, and delivered to a single patient within six months.

What Does "First Successful" CRISPR in Humans Actually Mean?

When you hear "first successful CRISPR in humans," the claim's meaning depends entirely on which milestone you're measuring. In 2016, Chinese researchers modified immune cells outside the body before reintroduction. Then Casgevy pioneered editing stem cells externally for sickle cell disease.

In 2019, Editas Medicine's EDIT-101 demonstrated in vivo delivery directly into retinal tissue, advancing the specificity of CRISPR systems for targeted organ treatment. But February 2025 redefined the benchmark entirely. Patient KJ received the first personalized, single-patient base editing therapy, correcting one specific genetic variant through intravenous lipid nanoparticles. The researchers behind KJ's therapy designed and delivered the customized treatment within 6 months of targeting his specific CPS1 variant.

Each milestone reflects a different dimension of progress — the efficiency of different CRISPR approaches improved dramatically across each generation. "First successful" isn't one moment; it's a layered progression of increasingly precise interventions. Together, base and prime editors are estimated to account for roughly 90% of disease-causing mutations, suggesting the most impactful chapters of this progression are still being written.

How a 2013 Lab Experiment Proved CRISPR Could Work in Human Cells

Publishing these findings in peer-reviewed literature earned immediate validation in the scientific community. You can trace today's clinical trials directly back to this single experiment.

The cross-species success in human and mouse cells sparked global research interest, transforming CRISPR from theoretical possibility into a demonstrated laboratory tool capable of precision genetic modification. Charpentier and Doudna made this breakthrough more practical by fusing the crRNA and tracrRNA into a single guide RNA.

CRISPR is now being tested in clinical trials to combat serious conditions, with researchers working to treat cancer and blood disorders by removing cells, editing their DNA, and injecting the modified cells back into the body.

China's 2016 Trial: The First CRISPR Treatment in a Patient

The leap from lab bench to hospital bed happened faster than most scientists expected. In August 2016, Chinese oncologist Lu You and his team at Sichuan University's West China Hospital became the first to inject CRISPR-edited cells into a human patient. While the U.S. faced significant regulatory hurdles that delayed its own program, China moved quickly after receiving hospital approval on July 6, 2016.

The trial enrolled 22 lung cancer patients whose diseases had stopped responding to standard treatments. Researchers removed T cells from patients' blood, used CRISPR to delete the PD-1 gene, then infused the edited cells back. Twelve patients ultimately received treatment, with no serious side effects reported. The clinical implications were clear: CRISPR gene therapy was both feasible and safe in human patients. This approach mirrored the success of PD-1 blocking drugs like Keytruda and Opdivo, which had already demonstrated that freeing T cells to attack tumors could produce meaningful results.

Among the patients treated, the most notable response was seen in a 55-year-old woman who experienced initial tumor mass shrinkage and maintained disease stability for an impressive 75 weeks.

The 2019 Trial That Put CRISPR Inside the Human Body

Building on China's landmark ex vivo trials, scientists took an even bolder step in 2019: editing genes directly inside a living patient's body. Editas Medicine sponsored the first in vivo CRISPR trial, targeting Leber's congenital amaurosis, a rare inherited eye disease. They administered the initial dose in March 2020, completing the low-dose cohort by November 2020.

Unlike earlier ex vivo approaches, this method delivered CRISPR directly into the patient, raising the stakes for adverse events monitoring. Off-target edits could trigger unforeseen complications, including cancer, that mightn't surface immediately. That's why long term patient follow up became essential, with researchers tracking participants for years to assess both safety and effectiveness. No results had been publicly released at the time of initial reporting.

A more recent Phase 1 trial of the CRISPR-based therapy CTX310 demonstrated that a single intravenous infusion could reduce LDL cholesterol and triglycerides by up to 60% at the highest dose, with reductions observed within two weeks and sustained for at least 60 days.

The eye represents a promising target for CRISPR-based therapies because its relatively isolated environment limits the risk of systemic immune responses. Early results from ocular CRISPR trials have shown the technology is well-tolerated by patients, offering cautious optimism for those suffering from genetic forms of blindness like Leber congenital amaurosis.

How Casgevy Earned the First FDA Approval for a CRISPR Medicine

When Vertex Pharmaceuticals and CRISPR Therapeutics submitted their clinical data to the FDA, they weren't just seeking approval for a new drug—they were asking regulators to greenlight an entirely new class of medicine. The clinical evidence was compelling.

Trial participants with sickle cell disease saw near-complete elimination of vaso-occlusive crises, while those with transfusion-dependent β-thalassemia achieved transfusion independence. These regulatory milestones culminated on December 8, 2023, when the FDA approved Casgevy as the first CRISPR/Cas9-based therapy for patients 12 and older. The treatment model centers on a one-time procedure using your own edited stem cells, eliminating the need for chronic transfusions or risky donor transplants. Post-marketing requirements guarantee long-term monitoring of durability and safety. Sickle cell disease affects approximately 100,000 people in the U.S., with the vast majority of those impacted being Black Americans.

The FDA's approval of Casgevy for transfusion-dependent Beta Thalassemia arrived roughly two months ahead of schedule, underscoring the urgency regulators placed on bringing this breakthrough therapy to patients who face lifetime healthcare costs estimated to exceed $5 million.

Why Base Editing Is Considered CRISPR 2.0

Most gene editing milestones build on what came before, and base editing is no exception—except it fundamentally rewires how CRISPR works. Traditional CRISPR-Cas9 cuts both DNA strands, risking deletions, translocations, and cellular shutdown. Base editing skips those breaks entirely.

Instead of severing DNA, a modified Cas9 fused to a deaminase enzyme directly converts one base into another—C to T or A to G—through a single-stranded nick. That subtle shift delivers enhanced safety and reduced off-target effects, since you're not triggering NHEJ or homology-directed repair pathways.

This precision makes base editing especially powerful for correcting point mutations behind diseases like sickle cell anemia. You can target a single nucleotide, fix it chemically, and avoid the collateral damage that defined first-generation CRISPR approaches. Beam Therapeutics has already initiated a Phase 1/2 trial leveraging this capability to reactivate fetal hemoglobin in sickle cell disease patients. Beyond sickle cell disease, Beam Therapeutics is also developing donor-derived CAR T cells through base editing, expanding its clinical reach into cancer immunotherapy.

KJ and the World's First Personalized Base-Editing Treatment

The case of KJ—a baby diagnosed with carbamoyl phosphate synthetase 1 (CPS1) deficiency—marks the first time doctors designed and delivered a fully personalized base-editing therapy. This novel metabolic disorder treatment and rare disease patient advocacy breakthrough shows what's now possible in medicine:

1. Doctors identified KJ's exact mutation and built a custom base editor—NGC-ABE8e—targeting it specifically.
2. The therapy was developed, tested, and manufactured within 6 months.
3. Lipid nanoparticles delivered the editor directly to liver cells without double-strand DNA breaks.
4. Three infusions were administered between February and April 2025, with no adverse effects reported. The treatment was administered alongside immunosuppressants, a critical safety lesson carried forward from early gene therapy trials.

You're witnessing medicine's shift from treating populations to treating one person at a time. The final editor also incorporated the V106W mutation to reduce off-target RNA and DNA editing, making the treatment safer for KJ.

Six Months From Diagnosis to Treatment: How the KJ Therapy Was Built

How do you compress years of drug development into six months? You build on decades of prior research. CHOP and Penn had already spent years studying urea cycle disorders using custom base editors in mice, cutting therapy creation timelines from years to months before KJ ever received his diagnosis.

When KJ's CPS1 deficiency emerged in August 2024, teams immediately mapped the critical path, assigned specific responsibilities, and executed a patient-centric development process that left no room for delay. This unprecedented institutional collaboration united CHOP, Penn Medicine, UC Berkeley, IDT, Aldevron, and Acuitas Therapeutics. Each partner leveraged existing GMP facilities and manufacturing platforms rather than rebuilding from scratch.

The FDA granted approval within one week of the IND submission, and KJ received his first infusion on day 208 of his life. Unlike traditional CRISPR-Cas9, which creates double-strand DNA breaks, the base-editing approach used in KJ's therapy precisely swapped a single base in the CPS1 gene without cutting the DNA. Following his treatment, KJ has demonstrated meaningful clinical improvements, including developmental milestones such as walking and talking.

How Lipid Nanoparticles Delivered the KJ Base Editor Into Liver Cells

Once the base editor was ready, researchers needed a way to transport it safely through the bloodstream and into KJ's liver cells — that's where lipid nanoparticles (LNPs) came in.

LNPs encapsulated the mRNA encoding the base editor, using liver-specific targeting through ApoE-mediated uptake to deliver the therapy directly to hepatic cells. The multi-dose administration protocol spaced treatments 2–4 weeks apart, allowing monitoring between sessions.

They naturally accumulate in the liver after intravenous infusion

They enable re-administration, unlike viral delivery methods

Fractionated dosing reduced single-session exposure while maintaining effectiveness

Lower peak concentrations minimized acute inflammatory responses

This precise delivery system guaranteed the base editor reached its target efficiently and safely. KJ received his first infusion of k-abe on day 208 of his life, marking a pivotal milestone in bespoke gene therapy. Notably, no serious side effects were reported across all three doses administered to KJ, reinforcing the safety profile of LNP-based delivery for this type of customized therapy.

CRISPR Babies, Consent, and the Lines Scientists Agreed Not to Cross

While lipid nanoparticles represent a carefully regulated, consent-driven application of gene editing, not every chapter in CRISPR's history reflects that standard. In 2018, scientist He Jiankui announced the birth of twin girls whose embryos he'd edited using CRISPR–Cas9 to disable the CCR5 gene, aiming to confer HIV resistance. A third edited baby followed in 2019.

The experiment crossed multiple lines scientists had agreed not to cross. Consent materials downplayed unknown risks, and recruiting through an HIV support organization created undue influence on participants. Neither twin received a known protective variant; instead, they carried non-standard genetic allele modifications never previously characterized in humans. Since germline edits are heritable, those children and their future descendants now carry consequences they never consented to.

He Jiankui was found guilty of illegal medical practice in December 2019 and sentenced to three years in prison along with a fine of three million yuan. The CRISPR-Cas9 tool he misused had only been developed years earlier by Jennifer Doudna and Emmanuelle Charpentier, work that earned them the Nobel Prize in Chemistry in 2020.